Advertisement

Bisphosphonate Therapy for Postmenopausal Osteoporosis

  • Henry Bone

Summary

  • The modern bisphosphonates are bone-specific, non-hormonal antiresorptive agents that reduce bone turnover and increase bone density. The best-studied examples are alendronate and risedronate, which have been shown to decrease the risk of vertebral and non-vertebral fractures.

  • Used properly, oral aminobisphosphonates are the mainstay of current practice. The development of additional drugs in this class, including intravenously administered agents, promises to expand the role of this important class.

Keywords

Bone Mass Bone Density Zoledronic Acid Postmenopausal Osteoporosis Bisphosphonate Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  1. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28(5):465–73 [discus ses mechanisms of action].PubMedCrossRefGoogle Scholar
  2. Black DM, Thompson DE, Bauer DC, et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124.Google Scholar
  3. Black DM, Greenspan, SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349(13):1207–15.PubMedCrossRefGoogle Scholar
  4. Bone HG. (2000) Development and Evaluation of New Drugs for Osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds). Osteoporosis, 2nd edn. San Diego: Academic Press, pp. 533–538.Google Scholar
  5. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates J, Lombardi A (2000) Alendronate and estrogen effects on post-menopausal women with low bone mineral density. Alendronate and estrogen effects on post-menopausal women with low bone mineral density 85(2): 720–6.Google Scholar
  6. Bone H, Hosking D, Devogelaer JP, Tucci R, Emkey R, Tonino R, Rodriguez-Portales JA, Downs R, Gupta J, Santora A, Liberman U (2004) For the Alendronate Phase III Osteoporosis Treatment Study Group; Ten year experience with alendronate in the treatment of postmenopausal osteoporotic women. For the Alendronate Phase III Osteoporosis Treatment Study Group; Ten year experience with alendronate in the treatment of postmenopausal osteoporotic women 350:1189–1199.Google Scholar
  7. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer R, Delmas PD (2004) for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe. J Bone Miner Res (in press).Google Scholar
  8. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroidinduced bone loss: a twelve-month, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 42(11):2309–2318.PubMedCrossRefGoogle Scholar
  9. Committee for Proprietary Medicinal Products (CPMP) Efficacy Working Party. Note for Guidance on Involutional Osteoporosis in Women. 1999; CPMP/EWP/552/95. Available via http://emea.eu.int/htms/human/ewp/ewpfin.htmlGoogle Scholar
  10. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13(6):1051–1055.PubMedCrossRefGoogle Scholar
  11. Cummings SR, Palermo L, Browner W, et al. (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283(10):1318–1321.Google Scholar
  12. Eastell R. (2000) Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 237(5):439–447.CrossRefGoogle Scholar
  13. Ensrud KE, Black DM, Palermo L, et al. (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157(22):2617–2624.Google Scholar
  14. Food and Drug Administration (FDA). Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Issued April 1994. Available via http://www.fda.gov/cder/guidance/index.htmGoogle Scholar
  15. Frost HM (1979) Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop 143:227–244.PubMedGoogle Scholar
  16. Garnero P, Delmas PD (1996) New developments in biochemical markers for osteoporosis. Calcif Tissue Int 59 Suppl 1:S2–9.CrossRefGoogle Scholar
  17. Harris ST, Watts NB, Genant HK, et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352.Google Scholar
  18. Harris ST, Watts NB, Jackson RD, et al. (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95(6):557–567.Google Scholar
  19. Krieg M.A., Gillard-Berquer D, Comuz J., Burckhardt P., Gov J.J., Thiebaud D (1998) Intravenous pamidronate as treatment of osteoporosis after heart transplantation. Osteoporos Int 8(Suppl 3):114.Google Scholar
  20. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–40.PubMedCrossRefGoogle Scholar
  21. Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE (1999) Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 25(5):613–619.PubMedCrossRefGoogle Scholar
  22. Orwoll E, Ettinger M, Weiss S, et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9):604–610.Google Scholar
  23. Recker R, Stakkestad J, Chesnut C, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer R, Delmas P (2004) Clinical assessment of intravenous ibandronate injection once every 3 months in postmenopausal osteoporosis. Bone (in press)Google Scholar
  24. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4(5):404–409.PubMedCrossRefGoogle Scholar
  25. Reginster J, Minne HW, Sorensen OH, et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1): 83–9.Google Scholar
  26. Reid JR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Iaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier P (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346(9):653–61.PubMedCrossRefGoogle Scholar
  27. Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59(2):193–202.PubMedGoogle Scholar
  28. Rittmaster RS, Bolognese M, Ettinger MP, et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85(6):2129–2134.Google Scholar
  29. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32): 2643–58PubMedCrossRefGoogle Scholar
  30. Saag KG, Emkey R, Schnitzer TJ, et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292–299.Google Scholar
  31. Schnitzer T, Bone HG, Crepaldi G, et al. (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 12(1):1–12.Google Scholar
  32. Watts NB (2001) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27(1):197–214.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2004

Authors and Affiliations

  • Henry Bone

There are no affiliations available

Personalised recommendations